Topics

Momentum Back At Cipla In Q2 But Albuterol Delayed In US

19:36 EST 7 Nov 2019 | SCRIP

Cipla had a strong run across key businesses in Q2, with products like generic Sensipar retaining share in the US...

      

Related Stories

 

Original Article: Momentum Back At Cipla In Q2 But Albuterol Delayed In US

NEXT ARTICLE

More From BioPortfolio on "Momentum Back At Cipla In Q2 But Albuterol Delayed In US"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...